Basilea Pharmaceutica AG 0QNA.L Stock
Basilea Pharmaceutica AG Price Chart
Basilea Pharmaceutica AG 0QNA.L Financial and Trading Overview
| Basilea Pharmaceutica AG stock price | 41.01 CHF |
| Previous Close | 46.03 CHF |
| Open | 0 CHF |
| Bid | 0 CHF x 0 |
| Ask | 0 CHF x 0 |
| Day's Range | 0 - 0 CHF |
| 52 Week Range | 0 - 55.3 CHF |
| Volume | 868 CHF |
| Avg. Volume | 5.94K CHF |
| Market Cap | 4.96M CHF |
| Beta (5Y Monthly) | 0.792337 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.585 CHF |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
0QNA.L Valuation Measures
| Enterprise Value | 652.71M CHF |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.033556357 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 4.417 |
| Enterprise Value/EBITDA | 30.065 |
Trading Information
Basilea Pharmaceutica AG Stock Price History
| Beta (5Y Monthly) | 0.792337 |
| 52-Week Change | 38.67% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 55.3 CHF |
| 52 Week Low | 0 CHF |
| 50-Day Moving Average | 45.86 CHF |
| 200-Day Moving Average | 46.66 CHF |
0QNA.L Share Statistics
| Avg. Volume (3 month) | 5.94K CHF |
| Avg. Daily Volume (10-Days) | 4.75K CHF |
| Shares Outstanding | 10.87M |
| Float | 11.58M |
| Short Ratio | N/A |
| % Held by Insiders | 4.16% |
| % Held by Institutions | 31.64% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 8.22% |
| Operating Margin (ttm) | 14.08% |
| Gross Margin | 33.40% |
| EBITDA Margin | 14.69% |
Management Effectiveness
| Return on Assets (ttm) | 5.55% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 147.76M CHF |
| Revenue Per Share (ttm) | 12.46 CHF |
| Quarterly Revenue Growth (yoy) | -5.099% |
| Gross Profit (ttm) | 49.36M CHF |
| EBITDA | 21.71M CHF |
| Net Income Avi to Common (ttm) | 12.15M CHF |
| Diluted EPS (ttm) | -0.585 |
| Quarterly Earnings Growth (yoy) | 86.50% |
Balance Sheet
| Total Cash (mrq) | 84.66M CHF |
| Total Cash Per Share (mrq) | 7.08 CHF |
| Total Debt (mrq) | 187.14M CHF |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 2.343 |
| Book Value Per Share (mrq) | -1.733 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 7.06M CHF |
| Levered Free Cash Flow (ttm) | -2005875 CHF |
Profile of Basilea Pharmaceutica AG
| Country | United Kingdom |
| State | N/A |
| City | Allschwil |
| Address | Hegenheimermattweg 167b |
| ZIP | 4123 |
| Phone | 41 61 606 11 11 |
| Website | https://www.basilea.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 141 |
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing, a small-molecule inhibitor of DXR, as well as in phase ½ clinical trial for urothelial and gastric cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
Q&A For Basilea Pharmaceutica AG Stock
What is a current 0QNA.L stock price?
Basilea Pharmaceutica AG 0QNA.L stock price today per share is 41.01 CHF.
How to purchase Basilea Pharmaceutica AG stock?
You can buy 0QNA.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Basilea Pharmaceutica AG?
The stock symbol or ticker of Basilea Pharmaceutica AG is 0QNA.L.
How many shares does Basilea Pharmaceutica AG have in circulation?
The max supply of Basilea Pharmaceutica AG shares is 107.9K.
What is Basilea Pharmaceutica AG Price to Earnings Ratio (PE Ratio)?
Basilea Pharmaceutica AG PE Ratio is now.
What was Basilea Pharmaceutica AG earnings per share over the trailing 12 months (TTM)?
Basilea Pharmaceutica AG EPS is -0.585 CHF over the trailing 12 months.